Karas RH - Search Results

1

Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy.

Jafri H, Alsheikh-Ali AA, Karas RH. Jafri H, et al. Among authors: karas rh. J Am Coll Cardiol. 2010 Jun 22;55(25):2846-54. doi: 10.1016/j.jacc.2009.12.069. J Am Coll Cardiol. 2010. PMID: 20579542 Free article. Review.

2

Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.

Alsheikh-Ali AA, Karas RH. Alsheikh-Ali AA, et al. Among authors: karas rh. Am J Cardiol. 2004 Jun 1;93(11):1417-8, A9. doi: 10.1016/j.amjcard.2004.02.045. Am J Cardiol. 2004. PMID: 15165929

3

Risk of adverse events with fibrates.

Alsheikh-Ali AA, Kuvin JT, Karas RH. Alsheikh-Ali AA, et al. Among authors: karas rh. Am J Cardiol. 2004 Oct 1;94(7):935-8. doi: 10.1016/j.amjcard.2004.06.033. Am J Cardiol. 2004. PMID: 15464682

4

Adverse events with concomitant amiodarone and statin therapy.

Alsheikh-Ali AA, Karas RH. Alsheikh-Ali AA, et al. Among authors: karas rh. Prev Cardiol. 2005 Spring;8(2):95-7. doi: 10.1111/j.1520-037x.2005.4060.x. Prev Cardiol. 2005. PMID: 15860984 Free article.

5

High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count?

Alsheikh-Ali AA, Kuvin JT, Karas RH. Alsheikh-Ali AA, et al. Among authors: karas rh. Atherosclerosis. 2005 Jun;180(2):217-23. doi: 10.1016/j.atherosclerosis.2005.01.003. Atherosclerosis. 2005. PMID: 15910846 Review.

6

High-density lipoprotein cholesterol-raising strategies.

Kuvin JT, Alsheikh-Ali AA, Karas RH. Kuvin JT, et al. Among authors: karas rh. J Cardiovasc Pharmacol. 2006 Feb;47(2):196-204. doi: 10.1097/01.fjc.0000199684.20578.7c. J Cardiovasc Pharmacol. 2006. PMID: 16495756 Review.

7

Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.

Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Alsheikh-Ali AA, et al. Among authors: karas rh. Am J Cardiol. 2006 Nov 1;98(9):1231-3. doi: 10.1016/j.amjcard.2006.05.057. Epub 2006 Sep 7. Am J Cardiol. 2006. PMID: 17056335

8

Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).

Alsheikh-Ali AA, Karas RH. Alsheikh-Ali AA, et al. Among authors: karas rh. Am J Cardiol. 2007 Feb 1;99(3):379-81. doi: 10.1016/j.amjcard.2006.08.044. Epub 2006 Dec 8. Am J Cardiol. 2007. PMID: 17261402

9

Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.

Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Alsheikh-Ali AA, et al. Among authors: karas rh. J Am Coll Cardiol. 2007 Jul 31;50(5):409-18. doi: 10.1016/j.jacc.2007.02.073. Epub 2007 Jul 16. J Am Coll Cardiol. 2007. PMID: 17662392 Free article. Review.

10

Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.

Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Alsheikh-Ali AA, et al. Among authors: karas rh. Am J Cardiol. 2007 Nov 15;100(10):1499-501. doi: 10.1016/j.amjcard.2007.06.058. Epub 2007 Sep 27. Am J Cardiol. 2007. PMID: 17996508

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters